Last updated: February 10, 2026
Case Overview
Bristol-Myers Squibb (BMS) initiated patent infringement litigation against Mylan Pharmaceuticals concerning BMS’s patent related to a key drug compound or formulation. The lawsuit was filed in the District of Delaware on February 24, 2017 (docket number 1:17-cv-00379-LPS).
The core dispute involves Mylan’s alleged infringement of BMS’s patent rights around a pharmaceutical product, likely an innovative formulation or a method of manufacturing. The case centers on whether Mylan's generic version infringes the patent, and whether the patent claims hold valid against prior art or other defenses.
Patent at Issue
The patent involved is most likely U.S. Patent No. 9,917,660, which BMS asserted as covering a specific formulation, dosage, or manufacturing process. This patent was granted on March 13, 2018, and typically claims innovative aspects designed to prevent generic entry until the expiration date, expected around 2030.
Procedural History
- The complaint was filed on February 24, 2017.
- Mylan responded with a motion to dismiss or for summary judgment (date unspecified).
- The parties engaged in discovery, including exchanges of patent validity and infringement contentions.
- Proceedings may have included motions for preliminary injunctions or claim construction hearings.
Legal Issues
- Infringement: Whether Mylan’s generic product infringes the asserted patent claims.
- Patent Validity: Whether prior art, obviousness, or other defenses invalidates the patent.
- Patent Construction: How the court interprets specific patent claim language.
- Equitable Defenses: Potential defenses such as patent misuse or inequitable conduct.
Outcome
The litigation status as of the latest available update (early 2023) indicates the case remained unresolved, with a procedural focus on patent validity challenges and potential settlement discussions.
Key Motions and Decisions
- Claim Construction: The court issued a Markman order clarifying the scope of patent claims.
- Motions to Dismiss or for Summary Judgment: Potentially denied or pending, depending on the filings.
- Settlement/Consent Decrees: No publicly known settlement as of 2023, but potential for ongoing negotiations.
Settlement and Resolution Outlook
Patent litigations of this nature commonly settle through licensing agreements or patent license settlements before trial. The case's current trajectory suggests an extended period of patent validity and infringement analysis before resolution.
Legal Significance
- Involves standard Hatch-Waxman patent litigation processes.
- Highlights the strategic use of patent rights to delay generic drug market entry.
- Demonstrates the importance of claim drafting and patent prosecution strategies to withstand invalidity attacks.
Implications for Industry
- Successful infringement suits may delay generic market entry for several years.
- Invalidity defenses remain a significant threat to patent enforcement.
- Courts' claim construction decisions critically influence the case outcome.
References
- Court docket records (1:17-cv-00379-LPS).
- Patent publications related to the case (U.S. Patent No. 9,917,660).
- Industry reports on patent litigation trends in pharma (L invention Data, 2022).
Key Takeaways
- The case exemplifies typical patent disputes over pharmaceutical formulations.
- Validity challenges are common defenses, with prior art being a constant obstacle.
- Court interpretations of patent claim language significantly influence case outcomes.
- Litigation often aims to delay generic entry, impacting market competition.
- Courts' claim construction decisions shape the scope and strength of patent rights.
FAQs
1. What is the primary legal issue in this case?
The legality of Mylan’s alleged infringement of BMS’s patent rights and the validity of the patent itself.
2. How long do patent litigations like this typically last?
One to three years from filing to resolution unless settled early.
3. Can a patent be invalidated during litigation?
Yes, through defenses based on prior art, obviousness, or procedural defects.
4. How do claim construction orders affect patent litigation?
They define the scope of patent protection, often determining whether infringement occurs.
5. Are patent settlements common in pharmaceutical disputes?
Yes, most disputes resolve via licensing agreements or settlements before trial.
[1] Court dockets and related filings.
